AI assistant
Sending…
RELMADA THERAPEUTICS, INC. — Director's Dealing 2023
Dec 19, 2023
34465_dirs_2023-12-19_809a58ec-65eb-486e-a27f-582f7d1608e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2023-12-15
Reporting Person: TRAVERSA SERGIO (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-15 | Stock Option (right to buy) | $2.48 | A | 183881 | Acquired | 2033-12-15 | Common Stock (183881) | Direct |
Footnotes
F1: The options vest in 16 equal quarterly installments commencing on March 15, 2024.
More from RELMADA THERAPEUTICS, INC.
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Share Issue/Capital Change
2026
May 13
Regulatory Filings
2026
May 12
Capital/Financing Update
2026
Apr 9
Regulatory Filings
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 12
Capital/Financing Update
2026
Jan 30
Director's Dealing
2025
Dec 16